Bradley Campbell

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

National Tay-Sachs & Allied Diseases Association is a non-profit organization. The firm engages in the provision of funding, research, and support services for individual affected with Tay-Sachs, Canavan, Sandhoff, GM1 gangliosidosis, and related diseases. The company was founded in 1957 and is headquartered in Boston, MA.

BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart.

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY.

Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

ARYA Sciences Acquisition Corp III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which it refers to as its initial business combination. It has not yet selected any business combination target. The company was founded by Joseph Edelman, Adam Stone, Michael Altman, and Konstantin Poukalov on March 27, 2020 and is headquartered in New York, NY.